Discounted “Stopgap” PDUFA Renewal Might Prompt Faster FDARA Action
Executive Summary
A proposal circulated by House Democrats to renew user fee programs for three months while negotiations on FDA reform legislation continue is "not an option," Senate Health, Education, Labor and Pensions Committee Ranking Republican Michael Enzi, Wyo., has declared
You may also be interested in...
Generic Biologics Bill May Not Ride FDARA But Legislators Will Keep Pushing
House legislators assure the generics industry that they remain committed to generic biologics legislation, though the FDA reform bill reauthorizing the drug user fee program will move ahead without it
Benzodiazepine Coverage Among Medicare Provisions In Child Health Bill
Makers of benzodiazepines could see wider use of their products by Medicare Part D enrollees, under a provision of the child health/Medicare legislative package that cleared the House Ways and Means Committee July 27
Preemption Remains Conference Issue In FDA Bill As Both Sides Declare Victory
The impact of FDA reform legislation on product liability lawsuits could depend in large part on how the House and Senate resolve subtle differences in phrasing between the two chambers' bills